Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy

Jeroen Hendrikus Jacobus Paulissen*, Alexander Victor van Schoonhoven, Emma Olin, Arjan Jacobus Postma, Zacharie Mbanya, Kyle John Dunton, Maarten Jacobus Postma, Marinus van Hulst, Roel Donald Freriks

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

26 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions

Keyphrases